These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 22826702)
1. A changing landscape in castration-resistant prostate cancer treatment. Felici A; Pino MS; Carlini P Front Endocrinol (Lausanne); 2012; 3():85. PubMed ID: 22826702 [TBL] [Abstract][Full Text] [Related]
2. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East. Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901 [TBL] [Abstract][Full Text] [Related]
3. New and emerging treatments for advanced prostate cancer. George DJ; Kantoff PW; Lin DW Clin Adv Hematol Oncol; 2011 Jun; 9(6 Suppl 12):1-15. PubMed ID: 22361744 [TBL] [Abstract][Full Text] [Related]
4. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer. George DJ; Kantoff PW; Lin DW Clin Adv Hematol Oncol; 2011 Jun; 9(6):1-11; discussion 11-5. PubMed ID: 21941983 [TBL] [Abstract][Full Text] [Related]
5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931 [TBL] [Abstract][Full Text] [Related]
6. Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? Bitting RL; Armstrong AJ; George DJ Clin Med Insights Oncol; 2011; 5():325-32. PubMed ID: 22084621 [TBL] [Abstract][Full Text] [Related]
7. New and emerging agents for the treatment of castration-resistant prostate cancer. Higano CS; Crawford ED Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657 [TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases. Wen L; Valderrama A; Costantino ME; Simmons S Am Health Drug Benefits; 2019 May; 12(3):142-149. PubMed ID: 31346366 [TBL] [Abstract][Full Text] [Related]
9. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. El-Amm J; Aragon-Ching JB Ther Adv Med Oncol; 2013 Jan; 5(1):25-40. PubMed ID: 23323145 [TBL] [Abstract][Full Text] [Related]
10. Emerging novel therapies for advanced prostate cancer. Osanto S; Van Poppel H Ther Adv Urol; 2012 Feb; 4(1):3-12. PubMed ID: 22295041 [TBL] [Abstract][Full Text] [Related]
11. New therapies for castration-resistant prostate cancer: efficacy and safety. Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649 [TBL] [Abstract][Full Text] [Related]
12. Current treatment strategies for castration-resistant prostate cancer. Kim SJ; Kim SI Korean J Urol; 2011 Mar; 52(3):157-65. PubMed ID: 21461278 [TBL] [Abstract][Full Text] [Related]